Milrinone Pediatric Dose — Cardiovascular Infusions
Milrinone is a phosphodiesterase-3 (PDE-3) inhibitor with combined inotropic and vasodilatory (lusitropic) properties, acting by increasing intracellular cyclic AMP to enhance myocardial contractility and reduce afterload. It is used in pediatric patients for low cardiac output states, including postoperative congenital heart disease, decompensated heart failure, and cardiogenic shock. Unlike catecholamines, milrinone does not depend on beta-adrenergic receptors, making it useful in patients with downregulated adrenergic pathways.
Pediatric Dosing
- Optional Loading Dose: 25–50 mcg/kg IV/IO administered over 30–60 minutes (confirm with attending physician before administering)
- Continuous Infusion: 0.25–1 mcg/kg/min IV, titrated to hemodynamic response
The loading dose is not universally administered and carries risk of hypotension; it should only be given after explicit attending confirmation. Titrate the infusion within the stated range based on clinical response and tolerance.
Worked example — 20 kg child:
Loading dose range: 20 × 25 mcg/kg = 500 mcg to 20 × 50 mcg/kg = 1,000 mcg over 30–60 min
Infusion range: 20 × 0.25 mcg/kg/min = 5 mcg/min to 20 × 1 mcg/kg/min = 20 mcg/min
Indications and Clinical Context
Milrinone is indicated for pediatric patients with low cardiac output syndrome, most commonly encountered in the postoperative cardiac surgery setting, but also in acute decompensated cardiomyopathy and septic shock with myocardial dysfunction. Its dual mechanism of improving contractility while simultaneously reducing systemic and pulmonary vascular resistance makes it particularly valuable when elevated afterload is contributing to ventricular dysfunction. It is frequently used in PICU and cardiac ICU settings as part of a broader hemodynamic support strategy.
Because milrinone improves diastolic relaxation (lusitropy) in addition to systolic function, it is especially useful in patients with restrictive physiology or diastolic dysfunction. Consult institutional cardiac or critical care protocols for specific patient-population guidance and combination therapy with vasoactive agents.
Administration and Monitoring
Milrinone is administered intravenously (IV) or intraosseously (IO) as a continuous infusion via a dedicated lumen of a central venous catheter whenever possible, given the need for prolonged infusion and hemodynamic monitoring. The loading dose, if used, must be infused slowly over 30–60 minutes to minimize the risk of hypotension and arrhythmia — it should not be given as a rapid bolus. Consult institutional protocol for maximum infusion concentration and compatible diluents.
- Monitor: Blood pressure, heart rate, cardiac rhythm (continuous ECG), urine output, and clinical perfusion markers
- Adverse effects: Hypotension (most common), ventricular arrhythmias, thrombocytopenia with prolonged use
- Caution: Use with care in patients with hypovolemia, outflow tract obstruction, or significant hypotension; correct volume status before or during initiation
- Renal considerations: Milrinone is renally cleared; dose adjustment or close monitoring is warranted in patients with impaired renal function — consult institutional protocol
Disclaimer: This article is an educational reference summarizing standard pediatric dosing values. It is not a substitute for clinical judgment. Always verify doses against institutional protocols, the current edition of authoritative references (e.g., Lexicomp, Harriet Lane Handbook, PALS guidelines), the patient’s accurate weight, and any patient-specific factors (renal/hepatic function, allergies, comedications) before administration.